UK drugmaker misses consensus estimates on third-quarter revenues
AstraZeneca expects results from trials of the coronavirus vaccine it is developing with Oxford university by the end of the year, offering hope in the fight against a rapidly resurging pandemic.
Pascal Soriot, the company’s chief executive, on Thursday said that, if the vaccine worked, AstraZeneca would supply its data to regulators and apply for emergency approval “in as many countries as possible at the same time”.
“It is up to the regulators to decide on approval and how fast they do it is up to them,” said Mr Soriot. The European Medicines Agency and its UK equivalent, the Medicines and Healthcare products Regulatory Agency, are conducting rolling, or accelerated, reviews of this and other vaccine candidates.
The coronavirus pandemic has entered its second wave in Europe, with England and other countries now in their second lockdown. Infections are also rising again in the US.
On Wednesday, the head of the UK’s vaccine task force, Kate Bingham, said AstraZeneca had fallen short of its deal to provide 30m doses to the UK by end of the year.